Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype

This study changes the foundational understanding of how cancer cells hijack the bone marrow microenvironment and demonstrates that tumor cells induce senescence and metabolic changes in adipocytes, potentially driving new therapeutic directions. Bone marrow adipocytes (BMAd) have recently been implicated in accelerating bone metastatic cancers, such as acute myelogenous leukemia and breast cancer. Importantly, bone marrow adipose tissue (BMAT) expands with aging and obesity, two key risk factors in multiple myeloma disease prevalence, suggesting that BMAds may influence and be influenced by myeloma cells in the marrow. Here, we provide evidence that reciprocal interactions and cross-regulation of myeloma cells and BMAds play a role in multiple myeloma pathogenesis and treatment response. Bone marrow biopsies from patients with multiple myeloma revealed significant loss of BMAT with myeloma cell infiltration of the marrow, whereas BMAT was restored after treatment for multiple myeloma. Myeloma cells reduced BMAT in different preclinical murine models of multiple myeloma and in vitro using myeloma cell-adipocyte cocultures. In addition, multiple myeloma cells altered adipocyte gene expression and cytokine secretory profiles, which were also associated with bioenergetic changes and induction of a senescent-like phenotype. In vivo, senescence markers were also increased in the bone marrow of tumor-burdened mice. BMAds, in turn, provided resistance to dexamethasone-induced cell-cycle arrest and apoptosis, illuminating a new possible driver of myeloma cell evolution in a drug-resistant clone. Our findings reveal that bidirectional interactions between BMAds and myeloma cells have significant implications for the pathogenesis and treatment of multiple myeloma. Targeting senescence in the BMAd or other bone marrow cells may represent a novel therapeutic approach for treatment of multiple myeloma. Significance: This study changes the foundational understanding of how cancer cells hijack the bone marrow microenvironment and demonstrates that tumor cells induce senescence and metabolic changes in adipocytes, potentially driving new therapeutic directions.

[1]  F. Prósper,et al.  Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment , 2020, Haematologica.

[2]  Beatriz Gámez,et al.  Myeloma Cells Down‐Regulate Adiponectin in Bone Marrow Adipocytes Via TNF‐Alpha , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  G. Colditz,et al.  Elucidating Under-Studied Aspects of the Link Between Obesity and Multiple Myeloma: Weight Pattern, Body Shape Trajectory, and Body Fat Distribution , 2019, JNCI cancer spectrum.

[4]  P. L. Bergsagel,et al.  Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease , 2019, Science Translational Medicine.

[5]  Matthew S Macauley,et al.  Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model , 2019, Haematologica.

[6]  L. Liaw,et al.  Development of a 3D bone marrow adipose tissue model. , 2018, Bone.

[7]  Joshua M. Korn,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[8]  Liming Huang,et al.  Tumor-Infiltrating Podoplanin+ Fibroblasts Predict Worse Outcome in Solid Tumors , 2018, Cellular Physiology and Biochemistry.

[9]  H. Unverdi,et al.  Stromal podoplanin expression and its clinicopathological role in breast carcinoma. , 2018, The Malaysian journal of pathology.

[10]  H. Hua,et al.  PARP9 is overexpressed in human breast cancer and promotes cancer cell migration. , 2018, Oncology letters.

[11]  Jinhua Zhang,et al.  S100A4 protects mice from high-fat diet-induced obesity and inflammation , 2018, Laboratory Investigation.

[12]  J. Pettitt,et al.  The skeletal cell‐derived molecule sclerostin drives bone marrow adipogenesis , 2018, Journal of cellular physiology.

[13]  M. Reagan,et al.  Myeloma-Associated Adipocytes Exhibit Reduced Adipogenic Gene Expression and Delipidation , 2017 .

[14]  M. Reagan,et al.  New Bone Cell Type Identified as Driver of Drug Resistance in Multiple Myeloma: The Bone Marrow Adipocyte , 2017 .

[15]  N. LeBrasseur,et al.  Targeting cellular senescence prevents age-related bone loss in mice , 2017, Nature Medicine.

[16]  D. Hose,et al.  Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. , 2017, Blood.

[17]  M. Evans,et al.  Techniques to Induce and Quantify Cellular Senescence. , 2017, Journal of visualized experiments : JoVE.

[18]  R. Baron,et al.  Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. , 2017, Cell metabolism.

[19]  E. K. Parkinson,et al.  Fibroblast activation and senescence in oral cancer , 2017, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[20]  Benjamin G. Bitler,et al.  HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci , 2016, The Journal of cell biology.

[21]  T. Trotter,et al.  Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone. , 2016, The American journal of pathology.

[22]  U. Andersson,et al.  TLR4-dependant pro-inflammatory effects of HMGB1 on human adipocyte , 2016, Adipocyte.

[23]  S. Davison,et al.  Adipocytes contribute to the growth and progression of multiple myeloma: Unraveling obesity related differences in adipocyte signaling. , 2016, Cancer letters.

[24]  J. Delaissé,et al.  Early reversal cells in adult human bone remodeling: osteoblastic nature, catabolic functions and interactions with osteoclasts , 2016, Histochemistry and Cell Biology.

[25]  U. Galderisi,et al.  Myeloma cells can corrupt senescent mesenchymal stromal cells and impair their anti-tumor activity , 2015, Oncotarget.

[26]  R. Orlowski,et al.  Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation , 2015, Oncotarget.

[27]  L. Liaw,et al.  Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. , 2015, Bone.

[28]  N. LeBrasseur,et al.  The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs , 2015, Aging cell.

[29]  C. Castoro,et al.  Esophageal adenocarcinoma and obesity: peritumoral adipose tissue plays a role in lymph node invasion , 2015, Oncotarget.

[30]  D. Kaplan,et al.  Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. , 2014, Blood.

[31]  Asha A. Nair,et al.  High‐Resolution Molecular Validation of Self‐Renewal and Spontaneous Differentiation in Clinical‐Grade Adipose‐Tissue Derived Human Mesenchymal Stem Cells , 2014, Journal of cellular biochemistry.

[32]  Degui Zhi,et al.  The Bioenergetic Health Index: a new concept in mitochondrial translational research , 2014, Clinical science.

[33]  E. Haralambieva,et al.  BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFN&ggr;–STAT1–IRF1–p53 axis in diffuse large B-cell lymphoma , 2013, Journal of Cell Science.

[34]  L. Lagneaux,et al.  Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells , 2013, PloS one.

[35]  Bolin Liu,et al.  Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. , 2013, American journal of translational research.

[36]  A. Aponte,et al.  Platelet Mitochondrial Dysfunction is Evident in Type 2 Diabetes in Association with Modifications of Mitochondrial Anti-Oxidant Stress Proteins , 2011, Experimental and Clinical Endocrinology & Diabetes (Barth).

[37]  R. Kyle,et al.  Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. , 2011, Blood.

[38]  J. Gil,et al.  A role for CXCR2 in senescence, but what about in cancer? , 2009, Cancer research.

[39]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[40]  F. Davies,et al.  Proteomic evaluation of pathways associated with dexamethasone‐mediated apoptosis and resistance in multiple myeloma , 2007, British journal of haematology.

[41]  Rafael Fonseca,et al.  Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. , 2007, Cancer research.

[42]  K. Vanderkerken,et al.  Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells , 2007, Leukemia.

[43]  K. Kristiansen,et al.  Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. , 2006, Molecular endocrinology.

[44]  A. Strosberg,et al.  Chemokines control fat accumulation and leptin secretion by cultured human adipocytes , 2001, Molecular and Cellular Endocrinology.

[45]  R. Aguiar,et al.  BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. , 2000, Blood.

[46]  K. Anderson,et al.  Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. , 1997, Blood.

[47]  D. DeFranco,et al.  Selectivity of Cell Cycle Regulation of Glucocorticoid Receptor Function (*) , 1995, The Journal of Biological Chemistry.